ARCA biopharma, Inc. (NASDAQ:ABIO) Insider Fund Lp Funicular Purchases 42,914 Shares of Stock

ARCA biopharma, Inc. (NASDAQ:ABIOGet Rating) insider Fund Lp Funicular bought 42,914 shares of the business’s stock in a transaction on Monday, May 16th. The shares were acquired at an average price of $2.30 per share, with a total value of $98,702.20. Following the transaction, the insider now directly owns 2,482,117 shares of the company’s stock, valued at $5,708,869.10. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Fund Lp Funicular also recently made the following trade(s):

  • On Friday, May 13th, Fund Lp Funicular purchased 14,000 shares of ARCA biopharma stock. The stock was bought at an average price of $2.29 per share, for a total transaction of $32,060.00.
  • On Wednesday, May 11th, Fund Lp Funicular bought 24,596 shares of ARCA biopharma stock. The shares were acquired at an average price of $2.29 per share, for a total transaction of $56,324.84.
  • On Monday, May 9th, Fund Lp Funicular bought 49,221 shares of ARCA biopharma stock. The shares were acquired at an average price of $2.27 per share, for a total transaction of $111,731.67.
  • On Thursday, May 5th, Fund Lp Funicular bought 16,903 shares of ARCA biopharma stock. The shares were acquired at an average price of $2.27 per share, for a total transaction of $38,369.81.
  • On Monday, May 2nd, Fund Lp Funicular bought 1,259 shares of ARCA biopharma stock. The shares were acquired at an average price of $2.31 per share, for a total transaction of $2,908.29.
  • On Thursday, April 28th, Fund Lp Funicular bought 23,381 shares of ARCA biopharma stock. The shares were acquired at an average price of $2.32 per share, for a total transaction of $54,243.92.
  • On Monday, April 25th, Fund Lp Funicular bought 13,751 shares of ARCA biopharma stock. The shares were acquired at an average price of $2.29 per share, for a total transaction of $31,489.79.
  • On Monday, April 18th, Fund Lp Funicular bought 9,119 shares of ARCA biopharma stock. The shares were acquired at an average price of $2.31 per share, for a total transaction of $21,064.89.
  • On Thursday, April 14th, Fund Lp Funicular purchased 17,410 shares of ARCA biopharma stock. The stock was bought at an average cost of $2.33 per share, with a total value of $40,565.30.
  • On Monday, April 11th, Fund Lp Funicular purchased 4,655 shares of ARCA biopharma stock. The stock was bought at an average cost of $2.31 per share, with a total value of $10,753.05.

ABIO opened at $2.29 on Tuesday. The stock has a 50-day moving average price of $2.33 and a 200-day moving average price of $2.24. The firm has a market cap of $33.00 million, a PE ratio of -1.76 and a beta of 2.20. ARCA biopharma, Inc. has a 1 year low of $1.71 and a 1 year high of $3.90.

ARCA biopharma (NASDAQ:ABIOGet Rating) last posted its quarterly earnings results on Monday, March 14th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter.

Institutional investors and hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP raised its position in shares of ARCA biopharma by 238.9% in the 3rd quarter. GSA Capital Partners LLP now owns 441,945 shares of the biopharmaceutical company’s stock worth $1,308,000 after purchasing an additional 311,550 shares during the last quarter. Minerva Advisors LLC purchased a new position in ARCA biopharma in the 3rd quarter worth about $30,000. Vanguard Group Inc. raised its position in ARCA biopharma by 13.1% in the 1st quarter. Vanguard Group Inc. now owns 459,562 shares of the biopharmaceutical company’s stock worth $1,057,000 after buying an additional 53,279 shares during the last quarter. Geode Capital Management LLC raised its position in ARCA biopharma by 8.8% in the 3rd quarter. Geode Capital Management LLC now owns 95,358 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 7,699 shares during the last quarter. Finally, Morgan Stanley raised its position in ARCA biopharma by 952.5% in the 1st quarter. Morgan Stanley now owns 40,744 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 36,873 shares during the last quarter. 28.12% of the stock is owned by hedge funds and other institutional investors.

ARCA biopharma Company Profile (Get Rating)

ARCA biopharma, Inc, a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure.

See Also

Insider Buying and Selling by Quarter for ARCA biopharma (NASDAQ:ABIO)

Receive News & Ratings for ARCA biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma and related companies with MarketBeat.com's FREE daily email newsletter.